A diagnostic blood test for stroke is desirable but will likely require multiple proteins rather than a single “troponin.” Validating large protein panels requires large patient numbers. Mass spectrometry (MS) is a cost-effective tool for this task. We compared differences in the abundance of 147 protein markers to distinguish 20 acute cerebrovascular syndrome (ACVS) patients who presented to the Emergency Department of one urban hospital within < 24 h from onset) and from 20 control patients who were enrolled via an outpatient neurology clinic. We targeted proteins from the stroke literature plus cardiovascular markers previously studied in our lab. One hundred forty-one proteins were quantified using MS, 8 were quantified using antibody protein enrichment with MS, and 32 were measured using ELISA, with some proteins measured by multiple techniques. Thirty proteins (4 by ELISA and 26 by the MS techniques) were differentially abundant between mimic and stroke after adjusting for age in robust regression analyses (FDR < 0.20). A logistic regression model using the first two principal components of the proteins significantly improved discrimination between strokes and controls compared to a model based on age alone (p < 0.001, cross-validated AUC 0.93 vs. 0.78). Significant proteins included markers of inflammation (47%), coagulation (40%), atrial fibrillation (7%), neurovascular unit injury (3%), and other (3%). These results suggest the potential value of plasma proteins as biomarkers for ACVS diagnosis and the role of plasma-based MS in this area.
Albers G. Acute cerebrovascular syndrome: time for new terminology for acute brain ischemia. Nat Clin Pract Cardiovasc. 2006;3(10):521-. CrossRef
Lynch J, Blessing R, White W, Grocott H, Newman M, Laskowitz D. Novel diagnostic test for acute stroke. Stroke. 2004;2003;35(1):57–63. CrossRef
Allard L, Burkhard PR, Lescuyer P, Burgess JA, Walter N, Hochstrasser DF, et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem. 2005;51(11):2043–51. https://doi.org/10.1373/clinchem.2005.053942. CrossRefPubMed
Jauch E, Lindsell C, Broderick J, Fagan S, Tilley B, Levine S, et al. Association of serial biochemical markers with acute ischemic stroke—the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke. 2006;37(10):2508–13. https://doi.org/10.1161/01.STR.0000242290.01174.9e. CrossRefPubMed
Laskowitz D, Kasner S, Saver J, Remmel K, Jauch E, BRAIN Study Grp, et al. Clinical usefulness of a biomarker-based diagnostic test for acute stroke. The Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke. 2009;2008;40(1):77–85. CrossRef
Sharma R, Macy S, Richardson K, Lokhnygina Y, Laskowitz D. A blood-based biomarker panel to detect acute stroke. J Stroke Cerebrovasc Dis. 2014;23(5):910–8. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.07.034. CrossRefPubMed
Montaner J, Perea-Gainza M, Delgado P, Ribo M, Chacon P, Rosell A, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke. 2008;39(8):2280–7. https://doi.org/10.1161/STROKEAHA.107.505354. CrossRefPubMed
Montaner J, Mendioroz M, Delgado P, Garcia-Berrocoso T, Giralt D, Merino C, et al. Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: the S100B/RAGE pathway. J Proteome. 2012;75(15):4758–65. https://doi.org/10.1016/j.jprot.2012.01.033. CrossRef
George PM, Mlynash M, Adams CM, Kuo CJ, Albers GW, Olivot J. Novel TIA biomarkers identified by mass spectrometry-based proteomics. Int J Stroke. 2015;10(8):1204–11. CrossRef
Whiteley W, Chong W, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke a systematic review. Stroke. 2009;40(5):E380–9. https://doi.org/10.1161/STROKEAHA.108.528752. CrossRefPubMed
SpecTRA: an observational study of the verification of protein biomarkers in transient ischemic attack. (2017). Retrieved from http://clinicaltrials.gov/ct2 (Identification No. NCT03050099).
SpecTRA: a study of the validation of protein biomarkers in transient ischemic attack. (2017). Retrieved from http://clinicaltrials.gov/ct2 (Identification No. NCT03070067).
Ay H, Furie K, Singhal A, Smith W, Sorensen A, Koroshetz W. An evidence-based causative classification system for acute ischemic stroke. Ann Neurology. 2005;58(5):688–97. CrossRef
Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009;27(7):633–41. https://doi.org/10.1038/nbt.1546. CrossRefPubMedPubMedCentral
MacLean B, Tomazela D, Shulman N, Chambers M, Finney G, Frewen B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinform. 2010;26(7):966–8. https://doi.org/10.1093/bioinformatics/btq054. CrossRef
R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016. URL https://www.R-project.org/
Rousseeuw P, Croux C, Todorov V, Ruckstuhl A, Salibian-Barrera M, Verbeke T, et al. robustbase: Basic Robust Statistics. R package version 0.92–6. http://CRAN.R-project.org/package=robustbase
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistical Soc Series B (Methodological) 1995;57(1):289–300.
Stacklies W, Redestig H, Scholz M, Walther D, Selbig J. pcaMethods—a bioconductor package providing PCA methods for incomplete data. Bioinform. 2007;23(9):1164–7. https://doi.org/10.1093/bioinformatics/btm069. CrossRef
Smith G, Seaman S, Wood A, Royston P, White I. Correcting for optimistic prediction in small data sets. Am J of. Epidemiology. 2014;180(3):318–24.
- Differential Proteomics for Distinguishing Ischemic Stroke from Controls: a Pilot Study of the SpecTRA Project
A. M. Penn
M. L. Lesperance
A. M. Jackson
R. F. Balshaw
M. B. Bibok
D. S. Smith
K. K. Lam
S. B. Coutts
C. H. Borchers
- Springer US